Veru (VERU) Competitors

$2.22 +0.01 (+0.45%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$2.33 +0.11 (+4.73%)

As of 04:15 AM Eastern

VERU vs. MED, EL, IPAR, PBH, and HLF

Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Medifast (MED), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF). These companies are all part of the "personal products" industry.

How does Veru compare to Medifast?

Medifast (NYSE:MED) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

: Medifast currently has a consensus target price of $12.00, suggesting a potential downside of 5.85%. Veru has a consensus target price of $22.50, suggesting a potential upside of 913.51%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Medifast.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Medifast -5.78% -4.80% -3.83%
Veru N/A -83.63% -55.90%
: 95.5% of Medifast shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medifast $346.10M 0.41 -$18.67M -$1.83 N/A
Veru $16.89M 2.11 -$22.73M -$1.26 N/A
: In the previous week, Medifast had 13 more articles in the media than Veru. MarketBeat recorded 14 mentions for Medifast and 1 mentions for Veru. Medifast's average media sentiment score of 0.02 beat Veru's score of 0.00 indicating that Medifast is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medifast
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Medifast has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, meaning that its share price is 219% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Veru	N/A	-83.63%	-55.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$346.10M	0.41	-$18.67M	-$1.83	N/A
Veru	$16.89M	2.11	-$22.73M	-$1.26	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medifast and Veru tied by winning 8 of the 16 factors compared between the two stocks.

How does Veru compare to Estee Lauder Companies?

Estee Lauder Companies (NYSE:EL) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

: Veru has lower revenue, but higher earnings than Estee Lauder Companies. Estee Lauder Companies is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Estee Lauder Companies $14.33B 2.19 -$1.13B -$0.70 N/A
Veru $16.89M 2.11 -$22.73M -$1.26 N/A
: In the previous week, Estee Lauder Companies had 49 more articles in the media than Veru. MarketBeat recorded 50 mentions for Estee Lauder Companies and 1 mentions for Veru. Estee Lauder Companies' average media sentiment score of 0.74 beat Veru's score of 0.00 indicating that Estee Lauder Companies is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Estee Lauder Companies
20 Very Positive mention(s)
6 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Positive
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 55.2% of Estee Lauder Companies shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 13.1% of Estee Lauder Companies shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Veru has a net margin of 0.00% compared to Estee Lauder Companies' net margin of -1.67%. Estee Lauder Companies' return on equity of 20.66% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Estee Lauder Companies -1.67% 20.66% 4.15%
Veru N/A -83.63% -55.90%
: Estee Lauder Companies currently has a consensus price target of $101.00, suggesting a potential upside of 16.39%. Veru has a consensus price target of $22.50, suggesting a potential upside of 913.51%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Estee Lauder Companies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estee Lauder Companies
2 Sell rating(s)
9 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.40
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Estee Lauder Companies has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, indicating that its stock price is 219% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estee Lauder Companies	$14.33B	2.19	-$1.13B	-$0.70	N/A
Veru	$16.89M	2.11	-$22.73M	-$1.26	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estee Lauder Companies	20 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Estee Lauder Companies	-1.67%	20.66%	4.15%
Veru	N/A	-83.63%	-55.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estee Lauder Companies	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.40
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Estee Lauder Companies beats Veru on 11 of the 17 factors compared between the two stocks.

How does Veru compare to Interparfums?

Interparfums (NASDAQ:IPAR) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

: Interparfums currently has a consensus price target of $105.20, suggesting a potential upside of 10.96%. Veru has a consensus price target of $22.50, suggesting a potential upside of 913.51%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Interparfums.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interparfums
0 Sell rating(s)
3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.71
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interparfums $1.49B 2.03 $168.39M $5.27 17.99
Veru $16.89M 2.11 -$22.73M -$1.26 N/A
: In the previous week, Interparfums had 16 more articles in the media than Veru. MarketBeat recorded 17 mentions for Interparfums and 1 mentions for Veru. Interparfums' average media sentiment score of 0.50 beat Veru's score of 0.00 indicating that Interparfums is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Interparfums
2 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 55.6% of Interparfums shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 43.7% of Interparfums shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Interparfums has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, indicating that its stock price is 219% less volatile than the S&P 500.
: Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.55% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Interparfums 11.32% 15.55% 10.78%
Veru N/A -83.63% -55.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.49B	2.03	$168.39M	$5.27	17.99
Veru	$16.89M	2.11	-$22.73M	-$1.26	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Interparfums	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Interparfums	11.32%	15.55%	10.78%
Veru	N/A	-83.63%	-55.90%

Summary

Interparfums beats Veru on 14 of the 16 factors compared between the two stocks.

How does Veru compare to Prestige Consumer Healthcare?

Veru (NASDAQ:VERU) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

: Veru presently has a consensus price target of $22.50, suggesting a potential upside of 913.51%. Prestige Consumer Healthcare has a consensus price target of $76.50, suggesting a potential upside of 41.14%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Prestige Consumer Healthcare.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veru
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Prestige Consumer Healthcare
0 Sell rating(s)

4 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.43
: Prestige Consumer Healthcare has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veru $16.89M 2.11 -$22.73M -$1.26 N/A
Prestige Consumer Healthcare $1.14B 2.25 $214.60M $3.78 14.34
: In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 6 mentions for Prestige Consumer Healthcare and 1 mentions for Veru. Prestige Consumer Healthcare's average media sentiment score of 0.72 beat Veru's score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Prestige Consumer Healthcare
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 47.2% of Veru shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Veru has a beta of -1.19, indicating that its share price is 219% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.
: Prestige Consumer Healthcare has a net margin of 16.90% compared to Veru's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 12.02% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Veru N/A -83.63% -55.90%
Prestige Consumer Healthcare 16.90% 12.02% 6.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prestige Consumer Healthcare	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.11	-$22.73M	-$1.26	N/A
Prestige Consumer Healthcare	$1.14B	2.25	$214.60M	$3.78	14.34

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-83.63%	-55.90%
Prestige Consumer Healthcare	16.90%	12.02%	6.41%

Summary

Prestige Consumer Healthcare beats Veru on 12 of the 15 factors compared between the two stocks.

How does Veru compare to Herbalife?

Herbalife (NYSE:HLF) and Veru (NASDAQ:VERU) are both small-cap personal products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

: Herbalife has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.19, indicating that its stock price is 219% less volatile than the S&P 500.
: In the previous week, Herbalife had 11 more articles in the media than Veru. MarketBeat recorded 12 mentions for Herbalife and 1 mentions for Veru. Herbalife's average media sentiment score of 0.69 beat Veru's score of 0.00 indicating that Herbalife is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Herbalife
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Veru
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 47.2% of Veru shares are owned by institutional investors. 5.1% of Herbalife shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Herbalife currently has a consensus price target of $17.80, indicating a potential upside of 8.09%. Veru has a consensus price target of $22.50, indicating a potential upside of 913.51%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Herbalife.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Herbalife
0 Sell rating(s)
4 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.43
Veru
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Herbalife $5.04B 0.34 $228.30M $2.20 7.49
Veru $16.89M 2.11 -$22.73M -$1.26 N/A
: Herbalife has a net margin of 4.53% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -35.02% beat Veru's return on equity.
Company Net Margins Return on Equity Return on Assets
Herbalife 4.53% -35.02% 8.05%
Veru N/A -83.63% -55.90%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Herbalife	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Herbalife	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Herbalife	$5.04B	0.34	$228.30M	$2.20	7.49
Veru	$16.89M	2.11	-$22.73M	-$1.26	N/A

Company	Net Margins	Return on Equity	Return on Assets
Herbalife	4.53%	-35.02%	8.05%
Veru	N/A	-83.63%	-55.90%

Summary

Herbalife beats Veru on 10 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.47M	$8.22B	$6.28B	$11.90B
Dividend Yield	N/A	2.47%	2.74%	5.26%
P/E Ratio	-1.76	121.88	29.18	27.35
Price / Sales	2.11	8.04	507.94	85.59
Price / Cash	N/A	17.06	43.42	54.56
Price / Book	1.78	3.52	9.85	6.79
Net Income	-$22.73M	$223.69M	$3.55B	$332.68M
7 Day Performance	-1.33%	-0.03%	2.30%	2.55%
1 Month Performance	-10.48%	11.82%	6.45%	9.36%
1 Year Performance	-55.86%	4.18%	44.89%	45.22%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	1.757 of 5 stars	$2.22 +0.5%	$22.50 +913.5%	-55.8%	$35.47M	$16.89M	N/A	230	News Coverage Upcoming Earnings
MED Medifast	1.0927 of 5 stars	$10.77 -3.4%	$12.00 +11.5%	-2.0%	$123.01M	$385.79M	N/A	870	Earnings Report
EL Estee Lauder Companies	4.5067 of 5 stars	$77.25 -0.7%	$97.95 +26.8%	+48.2%	$28.15B	$14.33B	N/A	57,000	Earnings Report Dividend Announcement Analyst Forecast
IPAR Interparfums	3.4232 of 5 stars	$91.28 +0.1%	$105.20 +15.2%	-21.0%	$2.92B	$1.49B	17.42	530	Trending News Earnings Report Dividend Announcement
PBH Prestige Consumer Healthcare	4.2797 of 5 stars	$58.35 -1.0%	$76.50 +31.1%	-33.1%	$2.79B	$1.14B	15.44	540	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors